Here’s a summary of the provided text:
Key Findings:
* A combination of talquetamab and teclistamab showed a positive response in treating extramedullary myeloma, a especially challenging form of multiple myeloma.
* The treatment led to responses in patients with this type of myeloma.
Adverse Effects:
* Common side effects included oral symptoms, cytokine release syndrome, and skin reactions.
* Serious adverse events, including infections, were frequent, leading some patients to discontinue treatment or, in a small number of cases, to death.
Future Directions:
* Researchers aim to investigate using this dual-target approach earlier in the treatment process.
* Efforts will focus on improving safety,particularly through better monitoring and prevention of infections.
Sources:
* A study published in the New England Journal of Medicine (2026).
* A news release from the Mayo Clinic (December 10, 2025).
* Information from Mayo Clinic about multiple myeloma (December 20, 2024).
* Details of the clinical trial (RedirecTT-1) on ClinicalTrials.gov (updated December 19, 2025).
